Bausch Health Companies (BHC) – Analysts’ Recent Ratings Changes

Bausch Health Companies (NYSE: BHC) has recently received a number of price target changes and ratings updates:

• 5/15/2022 – Bausch Health Companies had its price target lowered by analysts at Royal Bank of Canada from $21.00 to $17.00. They now have an “outperform” rating on the stock.
• 5/11/2022 – Bausch Health Companies was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 5/11/2022 – Bausch Health Companies had its price target lowered by analysts at BMO Capital Markets from $26.00 to $15.00.
• 5/11/2022 – Bausch Health Companies had its price target lowered by analysts at Bank of America Co. from $25.00 to $12.00.
• 5/9/2022 – Bausch Health Companies had its price target lowered by analysts at Royal Bank of Canada from $32.00 to $21.00. They now have an “outperform” rating on the stock.
• 3/29/2022 – Bausch Health Companies was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 3/28/2022 – Bausch Health Companies was downgraded by analysts at TheStreet from a “c-” rating to a “d+” rating.

BHC opened at $10.77 on Tuesday. The firm has a market capitalization of $3.89 billion, a PE ratio of -9.45, a PEG ratio of 0.23 and a beta of 1.62. Bausch Health Companies Inc. has a twelve month low of $7.80 and a twelve month high of $32.54. The firm’s 50-day moving average price is $20.85 and its 200 day moving average price is $23.94.

Bausch Health Companies (NYSE:BHC – Get Rating) last posted its earnings results on Wednesday, February 23rd. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.19. The company had revenue of $2.20 billion for the quarter, compared to analyst estimates of $2.21 billion. Bausch Health Companies had a negative net margin of 4.89% and a negative return on equity of 649.29%. Bausch Health Companies’s revenue was down .8% on a year-over-year basis. During the same period in the previous year, the business posted $1.33 EPS. Equities analysts anticipate that Bausch Health Companies Inc. will post 4.25 EPS for the current year.

In other news, insider Joseph F. Gordon sold 3,889 shares of the business’s stock in a transaction that occurred on Tuesday, March 8th. The shares were sold at an average price of $21.76, for a total value of $84,624.64. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Robert Spurr sold 4,846 shares of the company’s stock in a transaction that occurred on Tuesday, March 15th. The stock was sold at an average price of $22.20, for a total transaction of $107,581.20. The disclosure for this sale can be found here. Insiders sold a total of 16,668 shares of company stock worth $378,570 over the last three months. Insiders own 13.75% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in BHC. PDT Partners LLC purchased a new stake in shares of Bausch Health Companies in the 1st quarter valued at approximately $1,325,000. Woodline Partners LP increased its position in shares of Bausch Health Companies by 1.1% in the 1st quarter. Woodline Partners LP now owns 1,013,462 shares of the company’s stock valued at $23,158,000 after purchasing an additional 10,944 shares during the last quarter. Poehling Capital Management INC. increased its position in shares of Bausch Health Companies by 11.1% in the 1st quarter. Poehling Capital Management INC. now owns 110,803 shares of the company’s stock valued at $2,532,000 after purchasing an additional 11,028 shares during the last quarter. Engineers Gate Manager LP increased its position in shares of Bausch Health Companies by 181.2% in the 1st quarter. Engineers Gate Manager LP now owns 51,393 shares of the company’s stock valued at $1,174,000 after purchasing an additional 33,115 shares during the last quarter. Finally, Atria Wealth Solutions Inc. purchased a new stake in shares of Bausch Health Companies in the 1st quarter valued at approximately $447,000. 73.38% of the stock is currently owned by hedge funds and other institutional investors.

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

Read More